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TACROLIMUS (Prograf-FK506) has been used since 1989 as a primary immunosuppressive agent in adult 
and pediatric renal transplant recipients at our institu-
tion.1.2 This report will summarize our experience with it 
over the past six years and will demonstrate its overall 
efficacy and superiority. 
Adults 
The early studies with tacrolimus. from 1989 through 1991, 
included a pilot series, a small randomized trial, and a 
larger nonrandomized group. I.3.4 When the outcome of 
these patients was compared with that in a roughly concur-
rent (although somewhat less challenging) group of cyclo-
sporine (CyA)-treated patients, equivalent patient and graft 
survival rates were seen. However, improved secondary 
outcomes were noted in the tacrolimus-treated patients, 
including lower steroid and antihypertensive medication 
requirements, and lower serum cholesterollevels.4 This led 
to a second prospective, randomized trial, between August, 
1991 and December, 1993, comparing two tacrolimus-based 
regimens, with and without azathioprine.5- 8 Earlier analy-
ses of this trial (by intention to treat, without patient 
censoring) demonstrated excellent outcomes with tacroli-
mus overall, but with unclear benefit for azathioprine. The 
most recent analysis, with a mean follow-up of 33 :!: 10 
months, showed a one- and three-year actuarial patient 
survival of 95% and 92%, with no significant difference 
between the two groups (Table 1). Overall one- and three-
year actuarial graft survival was 89% and 80%, with worse 
results in the tacrolimus/azathioprine/prednisone group 
than in the tacrolimus/prednisone group. Overall one- and 
three-year actuarial graft survival in first cadaver recipients 
was 91 % and 82%, without a statistically significant differ-
Table 1. Tacrolimus in Renal Transplantation Adults n = 397 
Tacro/Pred Tacrol AzaiPred Overall 
Actuarial Patient Survival 
1 year 97% 94% 95% 
3 year 94% 90% 92% 
Actuarial Graft Survival 
1 year 90% 88% 89% 
3 year' 84% 76% 80% 
'p = .031 
S. Creatinine (mgldL) 1.9:!: 1.0 1.9:!: 1.8 1.9:!: 1.5 
Off Steroids 70% 68% 69% 
Off Anti-Hypertensive 39% 36% 38% 
Medications 
Table 2. Tacrolimus in Renal Transplantation Pediatrics n = 43 
Actuarial Survival 
Patient Graft 
S. Creatinine 
Off Steroids 
Off Anti-Hypertensive 
Medications 
1 year 
100% 
98% 
1.2 :!: 0.6 mg/dL 
62% 
62% 
3 year 
100% 
85% 
ence between the two groups. The projected half-life of first 
cadaver kidneys was 11.9 :!: 2.5 years. 
Sixty-nine percent of successfully transplanted patients 
have been taken off steroids, and 38% are off antihyperten-
sive medications. The mean serum creatinine is 1.9 :!: 1.5 
mgldL. There are no differences between the double and 
triple drug groups in these parameters. The incidence of 
rejection was 50%, and steroid-resistant rejection was seen 
in 11 % of cases. There was a slightly lower. but not 
statistically different, incidence of rejection in the azathio-
prine group (45% vs 55% overall, and 8% vs 14% steroid 
resistance). There was also a substantial crossover between 
the two groups, more from triple to double therapy than 
vice versa. 
Subsequent to completion of the second randomized 
trial, a third randomized trial was begun in December, 1993, 
evaluating the role of one week of low-dose cyclophospha-
mide in tacrolimus-treated recipients. Analysis of this trial 
is currently in progress, and a fourth randomized trial, 
comparing tacrolimus/prednisone and tacrolimus/pred-
nisone/mycophenolate mofetil, has just begun. 
Pediatrics 
Between December, 1989 and December, 1993,43 pediatric 
patients received kidneys under tacrolimus-based immuno-
suppression (concomitant or previous liver recipients were 
excluded from this analysis).2 With a mean follow-up of 
25 :!: 14 months, overall one- and three-year actuarial 
patient survival was 100% (Table 2). Overall one- and 
three-year actuarial graft survival was 98% and 85%. Sixty-
two percent of the successfully transplanted children have 
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heen weaned o1l steroids. and 62<;, arc not taking anti-
hypertensive medications. The mean serum creatinine i, 
1.2 ::':: 0.6 mg/dL. The incidence of rejection was SW,. and 
the incidence of steroid resistant rejection was Y;. An 
additional 26 children were transplanted hetween January. 
1994 and July. 1995. with IOO'!, patient and graft survival. 
The overall experience with tacrolimus in Ollr renal 
transplant patients has heen gratifying. Better short-term 
graft survival. longer projected half-lives. and a remarkahle 
ability to wean from steroids in a majority of patients have 
heen the most notahle observations. Based on these find-
ings. we believe that taerolimus is a superior immunosup-
pressive agent in renal transplant recipients and is. at 
present. the drug of choice. The prolongation of cadaver 
kidney half-life in patients treated with tacrolimus is similar 
to that reported by Gjertson. Cecka. and Terasaki in a 
collection of cases compiled in the United Network for 
Organ Sharing (UN OS) Scientific Registry from 24 Amer-
ican renal transplant centers." Ongoing work is continuing 
to evaluate the role of new third agents and other modali-
ties (eg bone marrow augmentation) 10.11 in an effort to 
improve further the outcomes after transplantation. 
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